An investigation of novel treatment of prostate cancer through ubiquitinated protein accumulation
Project/Area Number |
23592355
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Urology
|
Research Institution | National Defense Medical College |
Principal Investigator |
SATO Akinori 防衛医科大学校(医学教育部医学科進学課程及び専門課程、動物実験施設、共同利用研究, 医学教育部医学科専門課程, 助教 (00296675)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | ユビキチン化蛋白蓄積 / 前立腺癌 / ユビキチン化蛋白 / 小胞体ストレス / ヒストンアセチル化 / ユビキチン化 / SAHA / bortezomib / ritonavir |
Research Abstract |
Unfolded proteins are normally repaired by the proteasome. I postulated that vorinostat or ritonavir increased unfolded proteins and bortezomib in combination would inhibit their degradation, leading to cell death. As expected, the combination therapies caused ubiquitinated proteins to accumulate in the cell and killed prostate cancer cells.
|
Report
(4 results)
Research Products
(17 results)